PainReform Ltd
PAINREFORM LTD is a Israel-based pharmaceutical Company. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.
Stock Performance Snapshot
Analyst Rating
Analysts recommend holding PainReform's stock with a target price of $12, indicating potential growth.
Financial Health
PainReform Ltd is generating strong cash flow, indicating a healthy financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PRFX
Beyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage potential
Scientific or clinical progress could create value over time, though timelines are uncertain and success is not guaranteed.
Clinical catalysts
Trial results and regulatory milestones tend to move micro‑cap biotech stocks sharply; both positive and negative outcomes matter.
Liquidity & dilution
Small market capitalisation often means thin trading and a likelihood of future fundraising which can dilute existing holders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
